Design and evaluation of hyaluronic acid-coated PLGA nanoparticles of raloxifene hydrochloride for treatment of breast cancer

References

• Coppola D. Molecular pathology and diagnostics of cancer. Springer; 2014.
   Google Scholar
• Banerjee D, Sengupta S. Nanoparticles in cancer chemotherapy. Progress in molecular biology and translational science. Vol. 104. Elsevier; 2011. p. 489–507.
   Google Scholar
• Egusquiaguirre SP, Igartua M, Hernández RM, et al. Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research. Clin Transl Oncol. 2012;14(2):83–93.
   PubMed Web of Science ®Google Scholar
• Brueggemeier RW, Hackett JC, Diaz-Cruz ES. Aromatase inhibitors in the treatment of breast cancer. Endocr Rev. 2005;26(3):331–345.
   PubMed Web of Science ®Google Scholar
• Chetrite GS, Cortes-Prieto J, Philippe JC, et al. Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. J Steroid Biochem Mol Biol. 2000;72(1–2):23–27.
   PubMed Web of Science ®Google Scholar
• Kendall A, Folkerd EJ, Dowsett M. Influences on circulating oestrogens in postmenopausal women: relationship with breast cancer. J Steroid Biochem Mol Biol. 2007;103(2):99–109.
   PubMed Web of Science ®Google Scholar
• McDonnell DP, Wardell SE, Norris JD. Oral selective estrogen receptor downregulators (SERDs), a breakthrough endocrine therapy for breast cancer. ACS Publications; 2015.
   Google Scholar
• Arango BA, Castrellon AB, Santos ES, et al. A review of the prevention of invasive breast cancer with raloxifene in postmenopausal women. Clin Med Ther. 2009;1:CMT.S2063.
   Google Scholar
• Gennari L, Merlotti D, Paola VD, et al. Raloxifene in breast cancer prevention. Expert Opin Drug Saf. 2008;7(3):259–270.
   PubMed Web of Science ®Google Scholar
• Kitchell JP, Wise DL. Poly(lactic/glycolic acid) biodegradable drug–polymer matrix systems. Methods Enzymol. 1985;112:436–448.
   PubMed Web of Science ®Google Scholar
• Jain AK, Das M, Swarnakar NK, et al. Engineered PLGA nanoparticles: an emerging delivery tool in cancer therapeutics. Crit Rev Ther Drug Carrier Syst. 2011;28(1):1–45.
   PubMed Web of Science ®Google Scholar
• Cerqueira BBS, Lasham A, Shelling AN, et al. Development of biodegradable PLGA nanoparticles surface engineered with hyaluronic acid for targeted delivery of paclitaxel to triple negative breast cancer cells. Mater Sci Eng C Mater Biol Appl. 2017;76:593–600.
   PubMed Web of Science ®Google Scholar
• Fakhari A, Berkland C. Applications and emerging trends of hyaluronic acid in tissue engineering, as a dermal filler and in osteoarthritis treatment. Acta Biomater. 2013;9(7):7081–7092.
   PubMed Web of Science ®Google Scholar
• Mattheolabakis G, Milane L, Singh A, et al. Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine. J Drug Target. 2015;23(7–8):605–618.
   PubMed Web of Science ®Google Scholar
• Wang S, Zhang J, Wang Y, et al. Hyaluronic acid-coated PEI–PLGA nanoparticles mediated co-delivery of doxorubicin and miR-542-3p for triple negative breast cancer therapy. Nanomedicine. 2016;12(2):411–420.
   PubMed Web of Science ®Google Scholar
• Mahira S, Kommineni N, Husain GM, et al. Cabazitaxel and silibinin co-encapsulated cationic liposomes for CD44 targeted delivery: a new insight into nanomedicine based combinational chemotherapy for prostate cancer. Biomed Pharmacother. 2019;110:803–817.
   PubMed Web of Science ®Google Scholar
• Muntimadugu E, Kumar R, Saladi S, et al. CD44 targeted chemotherapy for co-eradication of breast cancer stem cells and cancer cells using polymeric nanoparticles of salinomycin and paclitaxel. Colloids Surf B Biointerfaces. 2016;143:532–546.
   PubMed Web of Science ®Google Scholar
• Kommineni N, Mahira S, Domb AJ, et al. Cabazitaxel-loaded nanocarriers for cancer therapy with reduced side effects. Pharmaceutics. 2019;11(3):141.
   Web of Science ®Google Scholar
• Rajput N. Methods of preparation of nanoparticles—a review. Int J Adv Eng Technol. 2015;7(6):1806.
   Google Scholar
• Kwon H-Y, Lee J-Y, Choi S-W, et al. Preparation of PLGA nanoparticles containing estrogen by emulsification–diffusion method. Colloids Surf A. 2001;182(1–3):123–130.
   Google Scholar
• Astete CE, Sabliov CM. Synthesis and characterization of PLGA nanoparticles. J Biomater Sci Polym Ed. 2006;17(3):247–289.
   PubMed Web of Science ®Google Scholar
• Alam N, Koul M, Mintoo MJ, et al. Development and characterization of hyaluronic acid modified PLGA based nanoparticles for improved efficacy of cisplatin in solid tumor. Biomed Pharmacother. 2017;95:856–864.
   PubMed Web of Science ®Google Scholar
• Bhatnagar P, Kumari M, Pahuja R, et al. Hyaluronic acid-grafted PLGA nanoparticles for the sustained delivery of berberine chloride for an efficient suppression of Ehrlich ascites tumors. Drug Deliv Transl Res. 2018;8(3):565–579.
   PubMedGoogle Scholar
• Wu J, Zhang J, Deng C, et al. Vitamin E-oligo(methyl diglycol l-glutamate) as a biocompatible and functional surfactant for facile preparation of active tumor-targeting PLGA nanoparticles. Biomacromolecules. 2016;17(7):2367–2374.
   PubMed Web of Science ®Google Scholar
• Bhavsar D, Gajjar J, Sawant K. Formulation and development of smart pH responsive mesoporous silica nanoparticles for breast cancer targeted delivery of anastrozole: in vitro and in vivo characterizations. Microporous Mesoporous Mater. 2019;279:107–116.
   Web of Science ®Google Scholar
• Sahin A, Esendagli G, Yerlikaya F, et al. A small variation in average particle size of PLGA nanoparticles prepared by nanoprecipitation leads to considerable change in nanoparticles' characteristics and efficacy of intracellular delivery. Artif Cells Nanomed Biotechnol. 2017;45(8):1657–1664.
   PubMed Web of Science ®Google Scholar
• Saini D, Fazil M, Ali MM, et al. Formulation, development and optimization of raloxifene-loaded chitosan nanoparticles for treatment of osteoporosis. Drug Deliv. 2015;22(6):823–836.
   PubMed Web of Science ®Google Scholar
• Paswan SK, Saini T. Purification of drug loaded PLGA nanoparticles prepared by emulsification solvent evaporation using stirred cell ultrafiltration technique. Pharm Res. 2017;34(12):2779–2786.
   PubMed Web of Science ®Google Scholar
• Avasatthi V, Pawar H, Dora CP, et al. A novel nanogel formulation of methotrexate for topical treatment of psoriasis: optimization, in vitro and in vivo evaluation. Pharm Dev Technol. 2016;21(5):554–562.
   PubMed Web of Science ®Google Scholar
• Wang C-W, Yang S-P, Hu H, et al. Synthesis, characterization and in vitro and in vivo investigation of C3F8-filled poly(lactic-co-glycolic acid) nanoparticles as an ultrasound contrast agent. Mol Med Rep. 2015;11(3):1885–1890.
   PubMedGoogle Scholar
• Chiu MH, Prenner EJ. Differential scanning calorimetry: an invaluable tool for a detailed thermodynamic characterization of macromolecules and their interactions. J Pharm Bioallied Sci. 2011;3(1):39–59.
   PubMedGoogle Scholar
• Dillen K, Vandervoort J, Van den Mooter G, et al. Factorial design, physicochemical characterisation and activity of ciprofloxacin–PLGA nanoparticles. Int J Pharm. 2004;275(1–2):171–187.
   PubMed Web of Science ®Google Scholar
• Elella MHA, Mohamed RR, Sabaa MW. Synthesis of novel grafted hyaluronic acid with antitumor activity. Carbohydr Polym. 2018;189:107–114.
   PubMedGoogle Scholar
• Seju U, Kumar A, Sawant K. Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: in vitro and in vivo studies. Acta Biomater. 2011;7(12):4169–4176.
   PubMed Web of Science ®Google Scholar
• Han E-J, Chung A-H, Oh I-J. Analysis of residual solvents in poly(lactide-co-glycolide) nanoparticles. J Pharm Investig. 2012;42(5):251–256.
   Google Scholar
• Yang Y, Xie XY, Mei XG. Preparation and in vitro evaluation of thienorphine-loaded PLGA nanoparticles. Drug Deliv. 2016;23(3):777–783.
   Web of Science ®Google Scholar
• Kumar N, Chaurasia S, Patel RR, et al. Atorvastatin calcium encapsulated Eudragit nanoparticles with enhanced oral bioavailability, safety and efficacy profile. Pharm Dev Technol. 2017;22(2):156–167.
   PubMed Web of Science ®Google Scholar
• Khanal S, Adhikari U, Rijal NP, et al. pH-responsive PLGA nanoparticle for controlled payload delivery of diclofenac sodium. J Funct Biomater. 2016;7(3):21.
   PubMedGoogle Scholar
• Lu B, Lv X, Le Y. Chitosan-modified PLGA nanoparticles for control-released drug delivery. Polymers. 2019;11(2):304.
   PubMed Web of Science ®Google Scholar
• Dubey RD, Saneja A, Qayum A, et al. PLGA nanoparticles augmented the anticancer potential of pentacyclic triterpenediol in vivo in mice. RSC Adv. 2016;6(78):74586–74597.
   Google Scholar
• Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7(2):27–31.
   PubMedGoogle Scholar
• Battani S, Pawar H, Suresh S. Evaluation of oral bioavailability and anticancer potential of raloxifene solid lipid nanoparticles. J Nanosci Nanotechnol. 2014;14(8):5638–5645.
   PubMed Web of Science ®Google Scholar
• Van Herck H, Baumans V, Brandt C, et al. Blood sampling from the retro-orbital plexus, the saphenous vein and the tail vein in rats: comparative effects on selected behavioural and blood variables. Lab Anim. 2001;35(2):131–139.
   PubMedGoogle Scholar
• Shah NV, Seth AK, Balaraman R, et al. Nanostructured lipid carriers for oral bioavailability enhancement of raloxifene: design and in vivo study. J Adv Res. 2016;7(3):423–434.
   PubMed Web of Science ®Google Scholar
• Afif AI. EKSPRESI CD44+ SEBELUM dan SETELAH SORTING MACS (Studi Eksperimen In-vitro pada Sel MCF-7 Kanker Payudara): Fakultas Kedokteran UNISSULA; 2014.
   Google Scholar
• Senthilraja P, Kathiresan K. In vitro cytotoxicity MTT assay in Vero, HepG2 and MCF-7 cell lines study of marine yeast. J Appl Pharm Sci. 2015;5(3):80–84.
   Google Scholar
• Badisa RB, Darling-Reed SF, Joseph P, et al. Selective cytotoxic activities of two novel synthetic drugs on human breast carcinoma MCF-7 cells. Anticancer Res. 2009;29(8):2993–2996.
   PubMed Web of Science ®Google Scholar
• Lee M-K, Lim S-J, Kim C-K. Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials. 2007;28(12):2137–2146.
   PubMed Web of Science ®Google Scholar
• Ansari KA, Torne SJ, Vavia PR, et al. Paclitaxel loaded nanosponges: in-vitro characterization and cytotoxicity study on MCF-7 cell line culture. Curr Drug Deliv. 2011;8(2):194–202.
   PubMed Web of Science ®Google Scholar
• Guideline IHT. Stability testing of new drug substances and products. Q1A (R2) Curr Step. 2003;4:1–24.
   Google Scholar
• Muthu MS, Feng S-S. Pharmaceutical stability aspects of nanomedicines. Nanomedicine. 2009;4(8):857–860.
   PubMed Web of Science ®Google Scholar
• Chiesa E, Dorati R, Modena T, et al. Multivariate analysis for the optimization of microfluidics-assisted nanoprecipitation method intended for the loading of small hydrophilic drugs into PLGA nanoparticles. Int J Pharm. 2018;536(1):165–177.
   PubMedGoogle Scholar
• Kushwaha AK, Vuddanda PR, Karunanidhi P, et al. Development and evaluation of solid lipid nanoparticles of raloxifene hydrochloride for enhanced bioavailability. Biomed Res Int. 2013;2013:584549.
   PubMed Web of Science ®Google Scholar
• Tran TH, Ramasamy T, Cho HJ, et al. Formulation and optimization of raloxifene-loaded solid lipid nanoparticles to enhance oral bioavailability. J Nanosci Nanotechnol. 2014;14(7):4820–4831.
   PubMed Web of Science ®Google Scholar
• Dash S, Murthy PN, Nath L, et al. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm. 2010;67(3):217–223.
   PubMed Web of Science ®Google Scholar
• Wu J, Deng C, Meng F, et al. Hyaluronic acid coated PLGA nanoparticulate docetaxel effectively targets and suppresses orthotopic human lung cancer. J Control Release. 2017;259:76–82.
   PubMed Web of Science ®Google Scholar
• Thanh NT, Maclean N, Mahiddine S. Mechanisms of nucleation and growth of nanoparticles in solution. Chem Rev. 2014;114(15):7610–7630.
   PubMed Web of Science ®Google Scholar